All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

*Cryptosporidium*, the highly infectious protozoan that causes diarrhea in immunocompetent and immunocompromised subjects \[[@pntd.0004729.ref001]--[@pntd.0004729.ref004]\], is transmitted via contaminated water or food \[[@pntd.0004729.ref001],[@pntd.0004729.ref003],[@pntd.0004729.ref005]\], swimming or bathing in surface waters \[[@pntd.0004729.ref001],[@pntd.0004729.ref003]\] and by direct person-to-person contact \[[@pntd.0004729.ref006]\], particularly in developing country settings of suboptimal sanitation and limited access to safe drinking water \[[@pntd.0004729.ref001],[@pntd.0004729.ref003],[@pntd.0004729.ref004]\]. Clinical cryptosporidiosis ranges from self-limited mild diarrhea (most commonly) to more severe forms such as persistent diarrhea (lasting 14 days or more) leading to malnutrition, hospitalizations and even death \[[@pntd.0004729.ref001],[@pntd.0004729.ref002],[@pntd.0004729.ref005],[@pntd.0004729.ref007]--[@pntd.0004729.ref013]\]. Immunocompromised hosts, e.g., persons with HIV/AIDS and malnourished children in developing countries, are more prone to develop severe clinical illness \[[@pntd.0004729.ref001],[@pntd.0004729.ref014]\]. Fecal shedding of *Cryptosporidium* oocysts can persist for weeks after clinical illness resolves \[[@pntd.0004729.ref015],[@pntd.0004729.ref016]\]. Since *Cryptosporidium* oocysts tolerate chlorination, waterborne outbreaks also occur in industrialized countries \[[@pntd.0004729.ref001],[@pntd.0004729.ref003],[@pntd.0004729.ref005]\].

Recently, the Global Enteric Multicenter Study (GEMS) elucidated the relative importance of *Cryptosporidium* versus many other enteropathogens as a cause of medically-attended diarrhea in young children in developing countries of sub-Saharan Africa (SSA) and South Asia \[[@pntd.0004729.ref010]\], where most young child diarrheal deaths occur. *Cryptosporidium* was the second leading cause (5--15%) of moderate-to-severe diarrhea (MSD) in infants at all 7 GEMS study sites. *Cryptosporidium* remained a leading cause of MSD in toddlers age 12--23 months, ranking third after rotavirus and *Shigella*; 5--9% of all MSD cases in 5 of the 7 sites were attributable to *Cryptosporidium* \[[@pntd.0004729.ref010]\]. *Cryptosporidium*-associated MSD negatively impacted linear growth and significantly increased the risk of death in toddlers \[[@pntd.0004729.ref010]\]. A follow-on study, GEMS-1A, investigated *Cryptosporidium* in association with less-severe diarrhea (LSD) over a 1-year period in 6 of 7 GEMS sites; the LSD cases enrolled in GEMS-1A, like the MSD cases enrolled in GEMS, were pediatric patients who were brought to health care facilities.

We extrapolated GEMS site-specific burdens of *Cryptosporidium*-associated MSD and LSD in children age \<24 months to estimate *Cryptosporidium*-associated diarrhea burdens for the entire SSA region (except the Republic of South Africa) and the India/Pakistan/Bangladesh/Nepal/Afghanistan (I/P/B/N/A) region of South Asia, where \~80% of global young child deaths due to diarrheal disease occur \[[@pntd.0004729.ref017],[@pntd.0004729.ref018]\].

Methods {#sec006}
=======

Study design and population {#sec007}
---------------------------

GEMS was a prospective matched case-control study conducted for 36 months at 7 sites where demographic surveillance systems (DSS) regularly updated censused populations. Sites included: Basse, The Gambia; Bamako, Mali; Manhiça, Mozambique; Siaya County, Kenya; Kolkata, India; Mirzapur, Bangladesh; and Bin Qasim Town, Pakistan. The published rationale \[[@pntd.0004729.ref019]\], working assumptions \[[@pntd.0004729.ref020]\], epidemiological \[[@pntd.0004729.ref021]\], laboratory \[[@pntd.0004729.ref022]\], and statistical methods \[[@pntd.0004729.ref023]\] of GEMS are summarized below.

The GEMS sampling frame comprised children age \<60 months residing within each site's DSS area. Children brought to sentinel health centers (SHCs) serving each DSS were assessed for criteria for MSD (*vide infra*). Every fortnight, 8--9 cases were targeted for enrollment, per age stratum (0--11, 12--23 and 24--59 months), per site. Within 14 days of each case enrolled, we undertook to enroll 1--3 randomly selected age- and sex-matched controls from the same or nearby communities. MSD was defined as a new acute diarrheal episode (≥3 loose stools in the previous 24 hours, occurring after ≥7 diarrhea-free days, and beginning within the previous 7 days), and having some or severe dehydration, initiation of intravenous rehydration based on a clinician's judgment, visible blood in stools (dysentery), or hospitalization for diarrhea or dysentery. At enrollment, a standardized evaluation, anthropometric measurements, and a stool sample were obtained from cases and controls. A single follow-up home visit was carried out \~60 (range 49--91) days after enrollment, during which the vital status of cases and controls was recorded and anthropometric measurements were made.

GEMS-1A was a 1-year extension in which children with MSD and LSD were enrolled at the SHCs in 6 of 7 GEMS sites, while in Kenya only MSD cases were enrolled. LSD was defined as a new acute diarrhea case seen at SHCs that did not meet the definition of MSD. Data collection methods, including the \~60-day follow-up household visit, were otherwise identical to GEMS.

Laboratory procedures {#sec008}
---------------------

Case and control stool samples were tested for numerous enteropathogens \[[@pntd.0004729.ref010],[@pntd.0004729.ref022]\], including *Cryptosporidium*, which was detected using an enzyme immunoassay (EIA) (TechLab, Inc. Blacksburg, VA). A random subset of stool specimens from 3,809 GEMS MSD case-control pairs from across all sites was also tested for various enteropathogens using TaqMan Array Card (TAC)-based real-time polymerase chain reaction (PCR). Briefly, nucleic acid was extracted from stool specimens using the QIAamp Fast Stool DNA Mini kit (Qiagen, Valencia, CA). The TaqMan Array Card methodology compartmentalizes PCR reactions for 48 targets per specimen as previously described \[[@pntd.0004729.ref024]\]. For this project we included primers to amplify the 18S rRNA gene of *Cryptosporidium* species \[[@pntd.0004729.ref024]\] and primers for alleles of the LIB13 locus that differentiates *C*. *hominis* from *C*. *parvum* \[[@pntd.0004729.ref025]\]. The LIB13 locus is not known to be present in other *Cryptosporidium* species, other than a divergent sequence in *C*. *cuniculus* (GU327781). The assay did not amplify genomic DNA from *C*. *meleagridis* isolate TU1867. Specimens with cycle threshold (CT) values ≤40 were considered positive with the species identification assay. For specimens that did not yield a LIB13 result, we performed nested amplification of a longer fragment of the 18S gene rRNA \[[@pntd.0004729.ref026]\], as well as GP60 to try to identify the species \[[@pntd.0004729.ref027]\]. GP60 sequencing was also performed to subtype the available *C*. *parvum* and *C*. *hominis* specimens.

Estimating the burden attributable to *Cryptosporidium* {#sec009}
-------------------------------------------------------

Since *Cryptosporidium* was incriminated as a cause of MSD and LSD mainly among children aged \<24 months \[[@pntd.0004729.ref010]\], disease burden extrapolations focused on infants 0--11 and toddlers 12--23 months of age. Details of the analysis are presented in [Fig 1](#pntd.0004729.g001){ref-type="fig"}. For each site and age group, pathogen-specific attributable fractions (AFs), weighted according to calendar time and presence or absence of dysentery and adjusted for the presence of other pathogens, and annual attributable incidence (AI) rates for MSD during the 3 years of GEMS have been reported \[[@pntd.0004729.ref010]\]. Employing similar methodology \[[@pntd.0004729.ref010],[@pntd.0004729.ref023],[@pntd.0004729.ref028]\], GEMS-1A data were used to estimate *Cryptosporidium*-attributable incidence of LSD, for site/age groups in which *Cryptosporidium* was associated with LSD with P\<0.1 after adjustment for other pathogens. Data from GEMS and GEMS-1A were used to estimate odds ratios (ORs) for *Cryptosporidium* and MSD by 6-month age interval for children aged 0--23 months; weighting by time or presence of dysentery should have little effect on associations with *Cryptosporidium*, and it was not employed in this analysis.

![Flow chart of steps and methods used in calculating the burden attributable to *Cryptosporidium* diarrhea.\
AF: attributable fraction, DSS: Demographic Surveillance systems, GEMS: Global Enteric Multicenter Study, HUAS: Health care utilization and attitudes surveys, region, LSD: less severe diarrhea, MSD: moderate-to-severe diarrhea, OR: odds ratio, SHC: sentinel health centers \* I/P/B/N/A: India, Pakistan, Bangladesh, Nepal and Afghanistan countries of South Asia; SSA: sub-Saharan Africa (excluding South Africa).](pntd.0004729.g001){#pntd.0004729.g001}

*Cryptosporidium*-specific AFs and AI rates, healthcare utilization rates for MSD and LSD, along with population estimates for the sites, were used to calculate overall *Cryptosporidium*-specific MSD and LSD AI rates separately for the 4 African sites (3 sites for LSD) and 3 Asian sites. These AI rates were extrapolated to the countries where GEMS sites were located, the 51 countries of the SSA region (excluding Republic of South Africa), and the India/Pakistan/Bangladesh/Nepal/Afghanistan (I/P/B/N/A) region of South Asia. For each country or region, the *Cryptosporidium* AI rate was multiplied by the total population (per United Nations estimates) \[[@pntd.0004729.ref029]\] to generate national and region-wide estimates of annual *Cryptosporidium*-attributable MSD and LSD cases. Since GEMS and GEMS-1A were conducted over 5 calendar years, we used the average UN estimated population size (for each GEMS country and region) of children 0--4 years of age during 2005--2010; we divided by 5 to estimate the number of children aged 0--11 and aged 12--23 months. To estimate 95% confidence intervals (CIs), we took the 2.5^th^ and 97.5^th^ percentiles of the number of *Cryptosporidium*-attributable diarrhea cases from 100,000 Monte Carlo simulations, assuming normal distributions for relevant parameters, with standard deviations estimated from Taylor series approximations. The proportions of *C*. *hominis* and *C*. *parvum* among the subset of cases (by PCR) were multiplied by the total number of *Cryptosporidium*-attributable diarrhea cases to estimate the species-specific attributable burdens.

Two strategies to estimate deaths among *Cryptosporidium*-associated diarrhea cases {#sec010}
-----------------------------------------------------------------------------------

The number of deaths among children aged \<24 months with *Cryptosporidium*-associated diarrhea over the \~60-day follow-up period following enrollment provided an extended case fatality risk (ECFR) \[[@pntd.0004729.ref010],[@pntd.0004729.ref021]\]. However, because GEMS and GEMS-1A were conducted in populations with high or moderate \<5 years mortality, and given numerous risk factors for death among children with MSD or LSD, some proportion of deaths among *Cryptosporidium*-associated diarrhea cases would have occurred unrelated to *Cryptosporidium* infection. Accordingly, we utilized two different analytical strategies to estimate more specifically the role of *Cryptosporidium* in deaths of children with *Cryptosporidium*-associated diarrheal illness.

*Cryptosporidium*-attributable deaths among *Cryptosporidium*-positive diarrhea cases in the population age \<24 months {#sec011}
-----------------------------------------------------------------------------------------------------------------------

First, we estimated the *Cryptosporidium*-attributable ECFR by subtracting the extended fatality risk (EFR) over the \~60-day observation period in GEMS/GEMS-1A controls from the ECFR in *Cryptosporidium*-positive cases. We used deaths in all controls, because the numbers of deaths among matched controls of *Cryptosporidium*-positive cases were very small. Multiplying the *Cryptosporidium*-attributable ECFR by the estimated number of *Cryptosporidium*-positive MSD and LSD cases in the region (SSA or I/P/B/N/A) provides a regional estimate of *Cryptosporidium*-attributable deaths.

Excess deaths among *Cryptosporidium*-attributable MSD and LSD cases {#sec012}
--------------------------------------------------------------------

We estimated the excess ECFR in *Cryptosporidium*-positive MSD and LSD cases relative to the ECFR in *Cryptosporidium*-negative cases by subtracting the ECFR in *Cryptosporidium*-negative cases from the ECFR in *Cryptosporidium*-positive cases. This excess risk represents the contribution of *Cryptosporidium* to death risk beyond both the background risk of death in the general pediatric population and that of diarrhea patients. The excess ECFR was then multiplied by the number of *Cryptosporidium*-attributable cases in each region, to estimate excess deaths among *Cryptosporidium*-attributable cases compared to the expected number of deaths if these cases had been *Cryptosporidium*-negative.

Estimates of *Cryptosporidium*-related deaths for the combined age group 0--23 months were calculated separately for MSD and LSD for the SSA region, given the much higher ECFR in children with MSD; deaths were estimated for MSD and LSD combined for the I/P/B/N/A region. Two-sided 95% CIs for differences in death risks were estimated by the Miettinen and Nurminen likelihood score method \[[@pntd.0004729.ref030]\]. CIs for numbers of deaths were estimated assuming normal distributions for numbers of deaths, with variances estimated from Taylor series approximations.

Statistical significance was defined as a two-sided P-value \<0.05. Analyses were performed using SAS version 9, IBM SPSS version 22, and NCSS 8.

Ethical approval {#sec013}
----------------

The study protocol was approved by ethics committees at the University of Maryland, Baltimore and at each field site \[[@pntd.0004729.ref021]\]. Parents/caregivers of participants provided written informed consent, and a witnessed consent was obtained for illiterate parents/caretakers.

Results {#sec014}
=======

Patterns of infection and diarrheal illness associated with *Cryptosporidium*, by age {#sec015}
-------------------------------------------------------------------------------------

Among 15,284 cases (12,110 MSD and 3,174 LSD) and 21,527 matched controls from GEMS-1 and GEMS-1A, *Cryptosporidium* data were missing for 11 cases (0.07%) and 10 controls (0.0046%) and these participants were excluded from analyses. Among the total 15,284 MSD and LSD cases, six (0.039%) had four matched controls rather than a maximum of three; these six deviations occurred in one African site during GEMS-1. The six extra matched controls were not censured from the dataset. Overall, *Cryptosporidium* was detected in stools from 1632 cases (10.7%) and 1184 controls (5.5%) (P\<0.001); positivity was significantly higher in MSD cases than matched controls in the age groups 0--11 and 12--23 months at all sites, and among the 24--59 month age group in Kenya. *Cryptosporidium* was also significantly more common in LSD cases than controls aged 0--11 and 12--23 months in Gambia and India, while in Mali and Mozambique this was found only in the toddler age group and in Pakistan only in infants and in children age 24--59 months ([Table 1](#pntd.0004729.t001){ref-type="table"}). Adjusted attributable incidence rates of *Cryptosporidium* LSD by site and age group are shown in [Table 2](#pntd.0004729.t002){ref-type="table"}.

10.1371/journal.pntd.0004729.t001

###### *Cryptosporidium* positivity (by EIA) in cases and controls by age, site, and severity of diarrhea.

![](pntd.0004729.t001){#pntd.0004729.t001g}

                                         Basse, The Gambia   Bamako, Mali                                   Manhiça, Mozambique   Siaya County, Kenya                            Kolkata, India   Mirzapur, Bangladesh                           Karachi, Pakistan                                                                                                                                                                                    
  -------------------------------------- ------------------- ---------------------------------------------- --------------------- ---------------------------------------------- ---------------- ---------------------------------------------- ------------------- ---------------------------------------------- ----------- ---------------------------------------------- ----------- ---------------------------------------------- ----------- ----------------------------------------------
  **MSD**                                **Cases**           **Controls**                                   **Cases**             **Controls**                                   **Cases**        **Controls**                                   **Cases**           **Controls**                                   **Cases**   **Controls**                                   **Cases**   **Controls**                                   **Cases**   **Controls**
  **Total number (age 0--11 months)**    520                 783                                            961                   961                                            439              883                                            829                 896                                            878         892                                            672         1122                                           788         788
  ***Cryptosporidium* (%)**              *16*.*0*            *6*.*3*[\*](#t001fn001){ref-type="table-fn"}   *16*.*6*              *6*.*9*[\*](#t001fn001){ref-type="table-fn"}   *19*.*8*         *8*.*8*[\*](#t001fn001){ref-type="table-fn"}   *14*.*4*            *5*.*8*[\*](#t001fn001){ref-type="table-fn"}   *15*.*3*    *6*.*7*[\*](#t001fn001){ref-type="table-fn"}   *8*.*2*     *3*.*4*[\*](#t001fn001){ref-type="table-fn"}   *14*.*1*    *9*.*1*[\*](#t001fn001){ref-type="table-fn"}
  **Total number (age 12--23 months)**   609                 894                                            911                   924                                            237              517                                            491                 808                                            752         778                                            579         967                                            512         902
  ***Cryptosporidium* (%)**              *12*.*3*            *5*.*0*[\*](#t001fn001){ref-type="table-fn"}   *9*.*4*               *6*.*9*[\*](#t001fn001){ref-type="table-fn"}   *16*.*5*         *9*.*9*[\*](#t001fn001){ref-type="table-fn"}   *11*.*0*            *4*.*8*[\*](#t001fn001){ref-type="table-fn"}   *14*.*4*    *8*.*2*[\*](#t001fn001){ref-type="table-fn"}   *6*.*0*     *3*.*3*[\*](#t001fn001){ref-type="table-fn"}   *10*.*9*    *5*.*7*[\*](#t001fn001){ref-type="table-fn"}
  **Total number (age 24--59 months)**   243                 503                                            845                   863                                            137              279                                            458                 744                                            477         923                                            463         1111                                           298         745
  ***Cryptosporidium* (%)**              *3*.*7*             *2*.*2*                                        *3*.*9*               *3*.*0*                                        *6*.*6*          *6*.*8*                                        *4*.*8*             *1*.*7*[\*](#t001fn001){ref-type="table-fn"}   *9*.*6*     *12*.*0*                                       *4*.*5*     *5*.*3*                                        *4*.*7*     *3*.*2*
  **LSD**                                **Cases**           **Controls**                                   **Cases**             **Controls**                                   **Cases**        **Controls**                                   **Cases**           **Controls**                                   **Cases**   **Controls**                                   **Cases**   **Controls**                                   **Cases**   **Controls**
  **Total number (age 0--11 months)**    220                 259                                            236                   236                                            155              154                                            NA                  NA                                             213         213                                            183         366                                            227         228
  ***Cryptosporidium* (%)**              *13*.*6*            *5*.*4*[\*](#t001fn001){ref-type="table-fn"}   *9*.*3*               *6*.*8*                                        *16*.*1*         *10*.*4*                                                                                                          *7*.*5*     *1*.*9*[\*](#t001fn001){ref-type="table-fn"}   *4*.*4*     *1*.*9*                                        *9*.*3*     *3*.*1*[\*](#t001fn001){ref-type="table-fn"}
  **Total number (age 12--23 months)**   202                 273                                            226                   227                                            175              175                                            NA                  NA                                             180         194                                            148         296                                            171         309
  ***Cryptosporidium* (%)**              *11*.*9*            *4*.*8*[\*](#t001fn001){ref-type="table-fn"}   *11*.*1*              *5*.*7*[\*](#t001fn001){ref-type="table-fn"}   *15*.*4*         *6*.*3*[\*](#t001fn001){ref-type="table-fn"}                                                                      *5*.*6*     *1*.*0*[\*](#t001fn001){ref-type="table-fn"}   *3*.*4*     *2*.*0*                                        *10*.*5*    *6*.*8*
  **Total number (age 24--59 months)**   135                 250                                            230                   230                                            101              101                                            NA                  NA                                             181         187                                            83          248                                            108         288
  ***Cryptosporidium* (%)**              *7*.*4*             *3*.*6*                                        *4*.*3*               *2*.*6*                                        *9*.*9*          *3*.*0*                                                                                                           *3*.*3*     *1*.*6*                                        *3*.*6*     *2*.*0*                                        *5*.*6*     *1*.*4*[\*](#t001fn001){ref-type="table-fn"}

\* P \< 0.05 for the difference between cases and controls, as obtained in unadjusted conditional logistic regression models.

MSD: moderate-to-severe diarrhea, LSD: less severe diarrhea, EIA: enzyme immune assay, NA: not applicable, the Kenyan site did not enroll LSD cases in the GEMS-1A component

10.1371/journal.pntd.0004729.t002

###### Adjusted attributable incidence (per 100 child-years) and 95% confidence intervals (CIs) of *Cryptosporidium*-attributable LSD, by site and age group[\*](#t002fn001){ref-type="table-fn"}.

![](pntd.0004729.t002){#pntd.0004729.t002g}

  Site/ age group (months)   Adjusted attributable incidence rate per 100 child-years (95% CI)
  -------------------------- -------------------------------------------------------------------
  **Gambia**                 
  0--11                      4.58 (-0.01--9.53)
  12--23                     3.49 (-0.01--6.98)
  24--59                     0.39 (-0.15--0.92)
  **Mali**                   
  0--11                      \-
  12--23                     3.92 (-3.10--10.95)
  24--59                     \-
  **Mozambique**             
  0--11                      5.36 (-4.90--15.62)
  12--23                     5.47 (-1.32--12.26)
  24--59                     \-
  **India**                  
  0--11                      4.73 (0.61--8.86)
  12--23                     3.43 (-0.78--7.64)
  24--59                     \-
  **Bangladesh**             
  0--11                      \-
  12--23                     \-
  24--59                     \-
  **Pakistan**               
  0--11                      8.46 (-0.03--16.95)
  12--23                     10.81 (-1.19--22.81)
  24--59                     0.93 (-0.24--2.09)

\* Weighted adjusted attributable incidence rates were calculated only for site/age groups in which *Cryptosporidium* was associated with LSD with P\<0.1 in multivariable conditional logistic regression models that adjusted for the presence of other enteric pathogens.

Note---LSD cases were not enrolled in Kenya during GEMS-1A

When MSD data were examined in narrower age groups, we found significant positive associations between *Cryptosporidium* and MSD at 4 sites (Mali, Mozambique, Kenya, India) in the first 5 months of life. ORs were higher at age 6--11 months, except in Mali. A significant OR between *Cryptosporidium* and MSD was observed in Mali, Mozambique, Kenya and India at ages 0--17 months. In Gambia and Pakistan, this association was significant from 6--23 months of age and in Bangladesh only at age 6--11 months. Adjusted AFs increased from age 0--5 months to age 6--11 months and were highest at age 6--11 months, except in Pakistan ([Table 3](#pntd.0004729.t003){ref-type="table"}).

10.1371/journal.pntd.0004729.t003

###### Association between *Cryptosporidium* (by EIA) and MSD from age 0--23 months by site during four years of surveillance: matched unadjusted and adjusted odds ratios (ORs) and adjusted attributable fractions (AF) with 95% confidence intervals (CIs)[\*](#t003fn001){ref-type="table-fn"}.

![](pntd.0004729.t003){#pntd.0004729.t003g}

  Site and age group (months)   Number of MSD cases   Number (%) of cases positive for *Cryptosporidium*   Number of controls   Number (%) of controls positive for *Cryptosporidium*   Unadjusted OR (95% CI)   P[^1^](#t003fn002){ref-type="table-fn"}   Adjusted OR (95% CI)                                                                                                                                             P[^2^](#t003fn003){ref-type="table-fn"}   Adjusted AF (95% CI)
  ----------------------------- --------------------- ---------------------------------------------------- -------------------- ------------------------------------------------------- ------------------------ ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ----------------------
  **Gambia**                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  \<6                           86                    7 (8.1)                                              123                  6 (4.9)                                                 1.60 (0.50--5.18)        0.43                                      1.99 (0.58--6.82)                                                                                                                                                0.28                                      4.0 (-3.0--11.1)
  6--11                         434                   76 (17.5)                                            660                  43 (6.5)                                                4.00 (2.47--6.47)        \<0.0001                                  4.41 (2.65--7.35)                                                                                                                                                \<0.0001                                  13.5 (9.3--17.8)
  12--17                        338                   45 (13.3)                                            478                  25 (5.2)                                                2.87 (1.62--5.08)        0.0003                                    2.61 (1.38--4.92)                                                                                                                                                0.003                                     8.2 (3.5--13.0)
  18--23                        271                   30 (11.1)                                            416                  20 (4.8)                                                2.48 (1.34--4.61)        0.004                                     3.23 (1.59--6.53)                                                                                                                                                0.001                                     7.6 (3.1--12.2)
  **Mali**                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  \<6                           230                   26 (11.3)                                            230                  4 (1.7)                                                 7.29 (2.34--22.71)       0.0006                                    6.59 (2.07--20.95)                                                                                                                                               0.001                                     9.6 (5.1--14.1)
  6--11                         731                   134 (18.3)                                           731                  62 (8.5)                                                2.58 (1.83--3.64)        \<0.0001                                  3.76 (2.48--5.70) (*Giardia* absent)[^3^](#t003fn004){ref-type="table-fn"} 1.24 (0.56--2.77) (*Giardia* present)[^3^](#t003fn004){ref-type="table-fn"}           \<0.0001 0.59                             12.3 (8.7--15.8)
  12--17                        527                   60 (11.4)                                            533                  40 (7.5)                                                1.70 (1.07--2.71)        0.025                                     1.81 (1.10--2.98)                                                                                                                                                0.019                                     5.1 (1.1--9.1)
  18--23                        384                   26 (6.8)                                             391                  24 (6.1)                                                1.10 (0.60--2.01)        0.76                                      1.06 (0.56--2.02)                                                                                                                                                0.85                                      0.4 (-3.9--4.7)
  **Mozambique**                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  \<6                           153                   22 (14.4)                                            293                  26 (8.9)                                                2.29 (1.18--4.43)        0.014                                     2.41 (1.17--4.98)                                                                                                                                                0.018                                     8.4 (2.0--14.8)
  6--11                         286                   65 (22.7)                                            589                  52 (8.8)                                                3.67 (2.32--5.83)        \<0.0001                                  5.71 (3.32--9.82)                                                                                                                                                \<0.0001                                  18.7 (13.2--24.3)
  12--17                        155                   28 (18.1)                                            330                  32 (9.7)                                                2.45 (1.35--4.42)        0.003                                     2.30 (1.19--4.44)                                                                                                                                                0.013                                     10.2 (2.7--17.8)
  18--23                        82                    11 (13.4)                                            187                  19 (10.2)                                               1.70 (0.74--3.91)        0.21                                      1.80 (0.70--4.63)                                                                                                                                                0.22                                      6.0 (-4.0--16.0)
  **Kenya**                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  \<6                           306                   37 (12.1)                                            329                  17 (5.2)                                                2.44 (1.33--4.46)        0.004                                     3.09 (1.55--6.16)                                                                                                                                                0.001                                     8.2 (3.7--12.7)
  6--11                         523                   82 (15.7)                                            567                  35 (6.2)                                                2.79 (1.81--4.31)        \<0.0001                                  3.31 (2.08--5.27)                                                                                                                                                \<0.0001                                  10.9 (7.2--14.7)
  12--17                        313                   38 (12.1)                                            516                  26 (5.0)                                                3.06 (1.75--5.37)        \<0.0001                                  3.75 (2.02--6.95)                                                                                                                                                \<0.0001                                  8.9 (4.7--13.1)
  18--23                        178                   16 (9.0)                                             292                  13 (4.5)                                                2.29 (1.02--5.17)        0.045                                     2.43 (1.01--5.86)                                                                                                                                                0.048                                     5.3 (-0.1--10.7)
  **India**                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  \<6                           298                   45 (15.1)                                            301                  22 (7.3)                                                2.35 (1.33--4.13)        0.003                                     2.44 (1.34--4.44)                                                                                                                                                0.003                                     8.9 (3.5--14.3)
  6--11                         580                   89 (15.3)                                            591                  38 (6.4)                                                2.97 (1.91--4.63)        \<0.0001                                  3.22 (1.90--5.47)                                                                                                                                                \<0.0001                                  10.6 (6.6--14.6)
  12--17                        458                   65 (14.2)                                            473                  33 (7.0)                                                2.20 (1.40--3.47)        0.0007                                    2.19 (1.23--3.87)                                                                                                                                                0.007                                     7.7 (2.9--12.5)
  18--23                        294                   43 (14.6)                                            305                  31 (10.2)                                               1.59 (0.91--2.77)        0.11                                      2.09 (0.99--4.40)                                                                                                                                                0.054                                     7.6 (0.9--14.3)
  **Bangladesh**                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  \<6                           165                   7 (4.2)                                              272                  10 (3.7)                                                1.21 (0.44--3.33)        0.70                                      0.92 (0.31--2.76)                                                                                                                                                0.88                                      -0.4 (-4.5--3.8)
  6--11                         507                   48 (9.5)                                             850                  28 (3.3)                                                3.06 (1.91--4.93)        \<0.0001                                  4.39 (2.15--8.96) (*C*. *jejuni* absent)[^4^](#t003fn005){ref-type="table-fn"} 0.79 (0.24--2.59) (*C*. *jejuni* present)[^4^](#t003fn005){ref-type="table-fn"}   \<0.00010.70                              5.7 (2.3--9.1)
  12--17                        341                   19 (5.6)                                             569                  18 (3.2)                                                1.97 (0.99--3.94)        0.054                                     2.23 (0.76--6.54)                                                                                                                                                0.14                                      3.1 (-1.1--7.2)
  18--23                        238                   16 (6.7)                                             398                  14 (3.5)                                                1.77 (0.84--3.73)        0.13                                      0.65 (0.15--2.78)                                                                                                                                                0.56                                      -3.6 (-16.1--9.0)
  **Pakistan**                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  \<6                           315                   35 (11.1)                                            315                  27 (8.6)                                                1.33 (0.78--2.25)        0.30                                      1.43 (0.77--2.65)                                                                                                                                                0.26                                      3.3 (-1.8--8.5)
  6--11                         473                   76 (16.1)                                            473                  45 (9.5)                                                1.81 (1.22--2.68)        0.003                                     2.91 (1.71--4.93) (*Aeromonas* absent)[^5^](#t003fn006){ref-type="table-fn"} 0.64 (0.16--2.60) (*Aeromonas* present)[^5^](#t003fn006){ref-type="table-fn"}       \<0.0001 0.54                             8.5 (3.3--13.7)
  12--17                        314                   31 (9.9)                                             550                  33 (6.0)                                                1.81 (1.04--3.14)        0.036                                     2.32 (1.24--4.34)                                                                                                                                                0.009                                     5.6 (1.6--9.6)
  18--23                        198                   25 (12.6)                                            352                  18 (5.1)                                                2.48 (1.28--4.79)        0.007                                     3.09 (1.47--6.50)                                                                                                                                                0.003                                     8.5 (3.3--13.8)

\* Table 3 includes data only from study children with *Cryptosporidium* results. EIA: enzyme immunoassay

^1^ These p-values were obtained from unadjusted conditional logistic regression analysis.

^2^ These p-values were obtained from adjusted conditional logistic regression analysis.

^3^ There is an interaction (P \< 0.1) between *Cryptosporidium* and *Giardia* for Mali at age 6--11 months.

^4^ There is an interaction (P \< 0.1) between *Cryptosporidium* and *C*. *jejuni* for Bangladesh at age 6--11 months.

^5^ There is an interaction (P \< 0.1) between *Cryptosporidium* and *Aeromonas* for Pakistan at age 6--11 months.

*Cryptosporidium* species {#sec016}
-------------------------

We identified *Cryptosporidium* species by PCR testing for 18S and Lib13 targets in a random subset of 3,809 case/control pairs. Samples with unresolved species by Lib13 (which only differentiates *C*. *hominis* from *C*. *parvum*) had species investigated by 18S and GP60 assays, as described in the Methods. This revealed 338 EIA+/PCR+ cases and 157 EIA+/PCR+ controls. Among the 338 samples from *Cryptosporidium*-positive MSD cases, 333 were suitable for further testing, of which 259 (77.8%), 33 (9.9%), 4 (1.2%), and 2 (0.6%), respectively, were positive for *C*. *hominis*, *C*. *parvum*, both *C*. *hominis* and *C*. *parvum* and *C*. *meleagridis*; the species of 35 (10.5%) specimens remained undetermined. Corresponding percentages in controls were 68.2%, 8.9%, 0.6%, 0.6%, and 21.0%. The species of one control sample (0.6%) was identified as *C*. *canis*. GP60 subtypes were identified on 71 EIA+/PCR+ specimens including 32 *C*. *hominis*, 37 *C*. *parvum*, and 2 *C*. *meleagridis*. Of 37 *C*. *parvum* infections, 34 (91.9%) were anthroponotic strains: 21 were IIc (19 A5G3 and 2 A4G3); 13 were IIe (1 IIeA6G1, 2 IIeA7G1, 7 IIeA10G1, 2 IIeA11, 1 IIeA15); all three non-anthroponotic strains were IIdA15G1. These derived from Mali (n = 13), Kenya (n = 9), Mozambique (n = 5), Pakistan (n = 7 including the 3 non-anthroponotic types), Bangladesh (n = 2), and Gambia (n = 1). Samples from Kenya and Mozambique were mostly IIcA5G3 (12/14). Mali's strains were diverse; containing 10/11 IIe strains as well as 3 IIcA5G3. The *C*. *hominis* subtypes included Ia (1 A18R2, 1 A19R2, 1 A23R2, 1 A24G1R2, 2 A25R2, 1 A26R2), Ib (3 A9G3, 8 A13G3), Id (1A14), Ie (exclusively 10 A11G3T3), and If (2 A14G1). Both *C*. *meleagridis* were subtyped as IIIdA6R1.

Disease burden {#sec017}
--------------

The *Cryptosporidium*-attributable MSD incidence was estimated to be 3.48 (95% CI, 2.27--4.67) and 3.18 (95% CI, 1.85--4.52) per 100 child-years in the African and Asian sites, respectively, in the 0--11 months age group. The respective incidences for toddlers aged 12--23 months were 1.41 (95% CI, 0.73--2.08) and 1.36 (95% CI, 0.66--2.05) per 100 child-years. Corresponding *Cryptosporidium*-attributable LSD incidence rates were 2.52 (95% CI, 0.33--5.01) and 4.88 (95% CI, 0.82--8.92) in infants and 4.04 (95% CI, 0.56--7.51) and 4.71 (95% CI, 0.24--9.18) in toddlers, per 100 child-years.

Applying these incidence rates to the pediatric population age \<2 years in the SSA and I/P/B/N/A regions, respectively, yielded annual estimated *Cryptosporidium* MSD burdens of \~1.2 million and \~1.5 million cases. The total number of LSD and MSD cases was estimated to be 2.9 million in this age group in SSA and 4.7 million in the populous I/P/B/N/A region ([Table 4](#pntd.0004729.t004){ref-type="table"}). The proportions of cases due to *C*. *hominis* and *C*. *parvum* in the subset tested for species were multiplied by the total estimated number of *Cryptosporidium*-attributable diarrhea cases in both regions (\~7.6 million), yielding estimates of 5.9 million *C*. *hominis*, 0.76 million *C*. *parvum* and 90,000 thousand co-infected (*C*. *hominis* plus *C*. *parvum*) cases in children aged \<2 years.

10.1371/journal.pntd.0004729.t004

###### Estimated number (in thousands) of diarrhea cases attributable to *Cryptosporidium* by age, country and region[^§^](#t004fn003){ref-type="table-fn"}.

![](pntd.0004729.t004){#pntd.0004729.t004g}

   Syndrome/age (months)                                  Gambia             Mali                 Mozambique            Kenya[\*\*](#t004fn004){ref-type="table-fn"}   India                        Bangladesh             Pakistan               Sub-Saharan Africa[^†^](#t004fn001){ref-type="table-fn"}   South Asia [\*](#t004fn002){ref-type="table-fn"}
  ------------------------------------------------------- ------------------ -------------------- --------------------- ---------------------------------------------- ---------------------------- ---------------------- ---------------------- ---------------------------------------------------------- --------------------------------------------------
  **MSD**                                                                                                                                                                                                                                                                                                    
  Age 0--11                                                                                                                                                                                                                                                                                                  
  Number (2.5^th^-97.5^th^ percentile)                    2.0 (1.4--2.9)     17.2 (12.0--25.1)    28.5 (19.9--41.5)     44.4 (31.1--64.8)                              784.5 (518.0--1,263.3)       100.9 (66.6--162.6)    129.6 (85.5--209.0)    880.5 (616.3--1,283.3)                                     1,068.0 (705.5--1,719.3)
  Age 12--23                                                                                                                                                                                                                                                                                                 
  Number (2.5^th^-97.5^th^ percentile)                    0.8 (0.5--1.4)     7.0 (4.1--11.9)      11.6 (6.8--19.7)      18.8 (10.6--30.8)                              334.7 (187.0--576.0)         43.0 (24.0--74.1)      55.3 (30.8--95.2)      357.2 (210.2--610.2)                                       455.7 (254.6--784.1)
  Age 0--23                                                                                                                                                                                                                                                                                                  
  Number (2.5^th^-97.5^th^ percentile)                    2.8 (2.1--3.8)     24.8 (17.7--32.7)    41.1 (29.5--54.0)     64.2 (46.0--84.3)                              1,119.2 (791.7--1,596.6)     143.9 (101.7--205.5)   184.8 (130.6--264.0)   1,237.7 (910.5--1,671.1)                                   1,523.8 (1,078.1--2,172.9)
  **LSD**[\*\*](#t004fn004){ref-type="table-fn"}                                                                                                                                                                                                                                                             
  Age 0--11                                                                                                                                                                                                                                                                                                  
  Number (2.5^th^-97.5^th^ percentile)                    1.5 (0.2--4.0)     12.5 (1.4--34.4)     20.7 (2.3--57.0)      32.3 (3.6--88.9)                               1,201.7 (314.2--2,469.2)     154.5 (40.3--317.4)    198.5 (51.7--407.6)    639.3 (71.9--1,761.9)                                      1,636.1 (427.4--3,361.4)
  Age 12--23                                                                                                                                                                                                                                                                                                 
  Number (2.5^th^-97.5^th^ percentile)                    2.3 (-1.5--9.5)    20.0 (-12.6--81.8)   33.1 (-20.7--135.7)   51.6 (-32.4--211.6)                            1,162.1 (219.9--2,687.4)     149.4 (28.3--345.6)    191.9 (36.3--443.8)    1,023.3 (-642.1--4,192.8)                                  1,582.1 (299.5--3,658.1)
  Age 0--23                                                                                                                                                                                                                                                                                                  
  Number (2.5^th^-97.5^th^ percentile)                    3.8 (-0.7--12.4)   32.5 (-6.4--106.6)   53.8 (-10.6--176.4)   83.9 (-16.6--275.1)                            2,363.8 (1,028.5--4,301.3)   303.9 (132.2--553.0)   390.4 (169.7--710.8)   1,662.6 (-329.0--5,451.8)                                  3,218.2 (1,400.5--5,855.6)
  **MSD & LSD** [\*\*](#t004fn004){ref-type="table-fn"}                                                                                                                                                                                                                                                      
  Age 0--11                                                                                                                                                                                                                                                                                                  
  Number (2.5^th^-97.5^th^ percentile)                    3.5 (1.8--6.0)     29.7 (15.8--52.0)    49.2 (26.3--86.0)     76.7 (40.9--134.1)                             1,986.3 (1,066.4--3,334.7)   255.4 (137.1--428.8)   328.0 (176.0--551.0)   1,519.8 (811.0--2,657.7)                                   2,704.1 (1,451.9--4,540.0)
  Age 12--23                                                                                                                                                                                                                                                                                                 
  Number (2.5^th^-97.5^th^ percentile)                    3.1 (-1.0--10.2)   26.9 (-8.2--87.5)    44.6 (-13.6--144.9)   69.7 (-21.3--226.1)                            1,496.8 (545.5--3,044.6)     192.5 (70.1--391.4)    247.2 (90.1--502.9)    1,380.5 (-421.6--4,479.7)                                  2,037.8 (742.6--4,147.8)
  Age 0--23                                                                                                                                                                                                                                                                                                  
  Number (2.5^th^-97.5^th^ percentile)                    6.6 (1.8--15.0)    56.6 (15.6--128.5)   93.8 (25.9--212.4)    146.4 (40.4--331.8)                            3,483.1 (2,118.7--5,481.1)   447.8 (271.5--705.3)   575.2 (348.6--906.1)   2,900.3 (800.6--6,575.0)                                   4,741.9 (2,874.8--7,462.5)

^†^ Countries and areas included in the extrapolations to sub-Saharan Africa region: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d\'Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mayotte, Mozambique, Namibia, Niger, Nigeria, Réunion, Rwanda, Saint Helena, São Tomé and Príncipe, Senegal, Seychelles, Sierra Leone, Somalia, Sudan, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia, and Zimbabwe \[[@pntd.0004729.ref029]\].

\* Extrapolation was made to the most populous countries in South Asia: India, Bangladesh, Pakistan, Afghanistan and Nepal \[[@pntd.0004729.ref029]\].

^§^ Data presented are estimated absolute numbers of cases attributable to *Cryptosporidium*, in parentheses are the 2.5^th^ and 97.5^th^ percentiles (corresponding to 95% confidence intervals), which were estimated by Monte Carlo simulations

\*\* Extrapolation of the combined incidence rate of the 3 African sites of GEMS-1A (Gambia, Mali, Mozambique) was made to the population of Kenya.

*Cryptosporidium*-attributable deaths among *Cryptosporidium*-positive diarrhea cases in the population and all diarrhea-attributable deaths {#sec018}
--------------------------------------------------------------------------------------------------------------------------------------------

Subtracting the EFR among all controls of MSD cases aged \<24 months at African sites (37/6258, 0.6%) from the ECFR among *Cryptosporidium*-positive MSD cases (41/643, 6.4%) ([Table 5](#pntd.0004729.t005){ref-type="table"}) yielded a *Cryptosporidium*-attributable ECFR of 5.8% (95% CI, 4.4%--7.6%). Similarly, subtracting the EFR in controls of LSD cases aged \<24 months at African sites (4/1261, 0.3%) from the ECFR among *Cryptosporidium*-positive LSD cases (1/139, 0.7%) produced an estimated *Cryptosporidium*-attributable ECFR of 0.4% (95% CI, -0.4%--3.7%). Multiplying these *Cryptosporidium*-attributable ECFRs by the numbers of *Cryptosporidium*-positive cases generated estimates of 107,000 *Cryptosporidium*-attributable MSD deaths (95% CI, 68,200--151,000) and 16,300 *Cryptosporidium*-attributable LSD deaths (95% CI, 0--75,200) in the SSA region. After subtracting the EFR in controls of MSD and LSD cases at Asian sites (6/6758, 0.09%) from the ECFR among *Cryptosporidium*-positive MSD and LSD cases combined (5/523, 1.0%) in the Asian sites and multiplying the resultant *Cryptosporidium*-attributable ECFR of 0.9% (95% CI, 0.4%--1.9%) by all *Cryptosporidium*-positive diarrhea cases, we estimate 78,900 (95% CI, 0--159,000) deaths attributable to *Cryptosporidium*-positive diarrhea in the (I/P/B/N/A) region. Thus, we estimate a total of \~202,000 *Cryptosporidium*-attributable diarrhea deaths in the two regions combined. Using the same methodology, we estimate 455,000 (95% CI, 280,000--630,000) annual diarrhea-attributable deaths in the SSA region and 254,000 (95% CI, 13,900--494,000) in the (I/P/B/N/A) region.

10.1371/journal.pntd.0004729.t005

###### Extended fatality risk during \~ 60 days following the onset of acute diarrhea among cases and controls aged 0--23 months[\*](#t005fn001){ref-type="table-fn"}.

![](pntd.0004729.t005){#pntd.0004729.t005g}

                                                     African sites                             Asian sites        
  -------------------------------------------------- --------------- ----- ------------------- ------------- ---- --------------------
  Total MSD cases                                    4552            169   3.7% (3.2%-4.3%)    3828          26   0.7% (0.4%-1.0%)
  *Cryptosporidium*-positive MSD cases               643             41    6.4% (4.6%-8.6%)    451           4    0.9% (0.2%-2.3%)
  *Cryptosporidium*-negative MSD cases               3909            128   3.3% (2.7%-3.9%)    3377          22   0.7% (0.4%-1.0%)
  All controls of MSD cases                          6258            37    0.6% (0.4%-0.8%)    5204          3    0.06% (0.01%-0.2%)
  Controls of *Cryptosporidium*-positive MSD cases   928             4     0.4% (0.1%-1.1%)    573           0    0.0% (0.0%-0.6%)
  Total LSD cases                                    1139            6     0.5% (0.2%-1.1%)    1035          5    0.5% (0.2%-1.1%)
  *Cryptosporidium*-positive LSD cases               139             1     0.7% (0.1%-3.9%)    72            1    1.4% (0.3%-7.5%)
  *Cryptosporidium*-negative LSD cases               1000            5     0.5% (0.2%-1.1%)    963           4    0.4% (0.2%-1.1%)
  All controls of LSD cases                          1261            4     0.3% (0.1%-0.8%)    1554          3    0.2% (0.07%-0.5%)
  Controls of *Cryptosporidium*-positive LSD cases   156             1     0.6% (0.02%-3.5%)   102           0    0.0% (0.0%-3.6%)

\* MSD: moderate-to-severe diarrhea (GEMS-1 and GEMS-1A data), LSD: less severe diarrhea (GEMS-1A data). This table includes data only for cases with *Cryptosporidium* results and non-missing data on vital status at follow-up, and their matched controls.

Excess deaths among *Cryptosporidium*-attributable MSD and LSD cases {#sec019}
--------------------------------------------------------------------

Subtracting the ECFR of *Cryptosporidium*-negative MSD cases (3.3%) from the ECFR of *Cryptosporidium*-positive MSD cases (6.4%) ([Table 5](#pntd.0004729.t005){ref-type="table"}) and multiplying the result by the number of *Cryptosporidium*-attributable MSD cases in the SSA region indicated that *Cryptosporidium* was responsible for an excess \~38,400 (95% CI, 13,400--68,100) MSD deaths among *Cryptosporidium*-attributable MSD cases. The analogous calculations based on LSD data ([Table 5](#pntd.0004729.t005){ref-type="table"}) suggested that *Cryptosporidium* led to \~3,600 (95% CI, -31,600--46,000) excess LSD deaths per year. In Asian sites the estimate of annual excess deaths in children \<24 months of age with *Cryptosporidium*-attributable diarrhea was \~16,900 (95% CI, -20,900--61,100). Thus, between the two regions we estimate that *Cryptosporidium* was responsible for \~59,000excess deaths in cases of *Cryptosporidium*-attributable diarrhea in children aged \<24 months, compared to the expected deaths in the same number of *Cryptosporidium*-negative cases.

Discussion {#sec020}
==========

There have been few attempts to estimate the burden of *Cryptosporidium* diarrheal disease in large populations. One exception is the *Cryptosporidium* burden estimate published for India \[[@pntd.0004729.ref031]\]. Others are the global *Cryptosporidium*-associated mortality estimates contained within Global Burden of Disease (GBD) and Child Epidemiology Estimation Group (CHERG) reports \[[@pntd.0004729.ref032]--[@pntd.0004729.ref034]\]. Three obstacles have heretofore impeded attempts to estimate region-wide *Cryptosporidium* disease burdens, including: 1) marked heterogeneity of clinical and laboratory methods used in studies of the etiology of pediatric diarrhea; 2) failure to take into account that many children without diarrhea also excrete *Cryptosporidium*; 3) a lack of species-specific data from clinical studies which might guide vaccine development efforts. In this paper, we utilized datasets and laboratory tests that allowed these obstacles to be overcome.

GEMS-1, pursued in representative sites in 7 developing countries, documented *Cryptosporidium* as a leading cause of endemic childhood diarrhea of a severity that brings children to healthcare facilities, particularly during the first 24 months of life \[[@pntd.0004729.ref010]\]. Importantly, GEMS-1 utilized rigorous standardized clinical, epidemiologic and laboratory methods to collect extensive data over several consecutive years in 7 sites. By including matched control children without diarrhea and adjusting for mixed infections with other enteropathogens, GEMS-1 quantified the specific role of *Cryptosporidium* in childhood diarrheal disease beyond the background carriage of *Cryptosporidium* \[[@pntd.0004729.ref010],[@pntd.0004729.ref023]\]. Finally, our results represent the first systematic, multisite, geographically-diverse assessment of the species-specific burden of *Cryptosporidium*-associated pediatric diarrhea, unequivocally corroborating the dominance of *C*. *hominis* \[[@pntd.0004729.ref007],[@pntd.0004729.ref035]--[@pntd.0004729.ref038]\] in infants and toddlers at all sites and revealing that 92% of *C*. *parvum* infections were due to recognized anthroponotic subtypes \[[@pntd.0004729.ref039]--[@pntd.0004729.ref041]\].

Despite our cautious extrapolation strategy, we found a substantial disease burden of \~7.6 million diarrhea cases annually attributable to *Cryptosporidium*, including \~2.9 million in SSA and \~4.7 million in the I/P/B/N/A region. Our estimated annual number of *Cryptosporidium*-attributable diarrhea cases (3.5 million) among Indian children aged \<24 months falls within the lower limit of the burden estimated by Sarkar *et al*. \[[@pntd.0004729.ref031]\].

GEMS-1 \[[@pntd.0004729.ref010]\] and other studies \[[@pntd.0004729.ref008],[@pntd.0004729.ref013],[@pntd.0004729.ref042]\] have demonstrated a negative impact of *Cryptosporidium*-associated diarrhea on linear growth (stunting), a nutritional insult that increases the risk for severe or fatal outcomes \[[@pntd.0004729.ref043],[@pntd.0004729.ref044]\]. The Malnutrition and Enteric Infections (MAL-ED) study prospectively followed birth cohorts in Peru, Brazil, Tanzania, South Africa, Pakistan, Bangladesh, Nepal and India with twice-weekly household visits through age 24 months \[[@pntd.0004729.ref045]\], thereby detecting mostly mild diarrheal episodes typically not observed in healthcare facility-based passive surveillance. Thus, MAL-ED provides data on the etiology of milder diarrheal illness and revealed *Cryptosporidium* to be the fifth most important diarrhea-associated pathogen in the first year of life and seventh most important in the second year of life \[[@pntd.0004729.ref045]\]. Regional burden estimates that we calculated did not incorporate the burden of milder clinical forms of *Cryptosporidium*-associated illness detected by active-surveillance household visits, as in MAL-ED, and thus probably under-estimates total burden.

The two models of the death burden in children with *Cryptosporidium* described in this manuscript demonstrated that among the 4 African sites MSD cases infected with *Cryptosporidium* at enrollment had a significantly increased ECFR during the subsequent \~60-days \[[@pntd.0004729.ref010]\] compared to the risk of death in controls and to the risk of death in *Cryptosporidium*-negative diarrhea cases. ECFR in children with *Cryptosporidium* in the African sites was particularly driven by Mozambique (high HIV prevalence) and rural Gambia (low HIV), suggesting that factors other than HIV infection, such as malnutrition, play a role in *Cryptosporidium*-related deaths in SSA. While overall mortality during the 60-day follow-up was much lower in the Asian sites \[[@pntd.0004729.ref010]\], nevertheless our estimates indicate a substantial *Cryptosporidium*-related death burden because of the enormity of the \<2 years population. Our GEMS-based estimates of deaths under 24 months attributable to *Cryptosporidium* diarrhea are greater than the estimates reported by GBD (35,200 deaths) \[[@pntd.0004729.ref033]\] and CHERG (12,000) \[[@pntd.0004729.ref034]\] among children age \<5 years. Discrepancies between GBD and CHERG estimates of \<5 years diarrheal disease mortality are recognized \[[@pntd.0004729.ref018],[@pntd.0004729.ref046],[@pntd.0004729.ref047]\]. Our estimates of total diarrhea-attributable deaths (455,000 and 254,000 in the SSA and I/P/B/N/A regions, respectively) are somewhat larger than estimates for children \<5 years of age for 2011 in a recent review \[[@pntd.0004729.ref048]\]. In large part these differences are likely because the GEMS estimates are uniquely based on follow-up information on deaths among laboratory-diagnosed *Cryptosporidium*-associated diarrhea cases, whereas CHERG and GBD estimates are based on deaths that occur acutely.

Our observational study design does not permit definitive determination of the direct causation between *Cryptosporidium*-positivity and deaths in young children. Nonetheless, the GEMS-based findings corroborate other results from West Africa \[[@pntd.0004729.ref009]\] highlighting *Cryptosporidium* as a very clear strong signal for children at increased risk for death. From a public health perspective, this is sufficient to plan interventions aimed at reducing the risk of death in such high-risk groups.

We observed a general age-specific pattern of *Cryptosporidium* infection and a strong association with MSD, with documentation of exposure in the first few months of life (in both cases and controls), a peak adjusted Attributable Fraction at age 6--11 months and a decrease thereafter ([Table 3](#pntd.0004729.t003){ref-type="table"}). We interpret this as reflecting a time-limited (first 5 months of life), passive protection mediated by maternally-transferred serum IgG as well as secretory IgA antibodies and other protective components of breast milk, despite exposure to the pathogen. Over the first two years of life, the prevalence of *Cryptosporidium* positivity in the controls remains impressively static documenting continuing exposure. However, beginning at \~6 months of age, clinical episodes of *Cryptosporidium*-associated diarrheal illness become more common and continue through age 23 months. By \~24 months of age these clinical and subclinical infections appear to induce in most toddlers acquired active immunity against further *Cryptosporidium* clinical illness. Support for this interpretation comes from a cohort study of Bedouin children in Southern Israel, a population under transition \[[@pntd.0004729.ref049]\]. Serum IgG and IgM antibodies to a *Cryptosporidium* oocyst lysate were measured in children ranging from neonates to toddlers age 23 months \[[@pntd.0004729.ref049]\]. High geometric mean titers (GMT) of serum IgG antibodies (of presumed maternal origin) were recorded at birth. GMT then decreased gradually until age 6 months, after which it increased progressively, as did the incidence of diarrheal illness and detection of *Cryptosporidium* in stools \[[@pntd.0004729.ref049]\]. Collectively, these observations can be interpreted as indicating that immunity against *Cryptosporidium* develops following natural exposure to the pathogen. Measurements of serum anti-gp15 antibody and clinical and sub-clinical infections were also monitored in a cohort of infants and toddlers in Vellore, India. Children who lacked anti-gp15 antibodies just before weaning had higher rates of *Cryptosporidium* infections (77%) than seropositive children (59%), although with the relatively small numbers in the cohort the difference did not reach statistical significance (p = 0.076) \[[@pntd.0004729.ref050]\].

Studies of infection-derived immunity in gnotobiotic piglets further support the notion of acquired immunity to *C*. *hominis*, as an initial induced *C*. *hominis* gastroenteritis in piglets significantly protected them against subsequent re-challenge with *C*. *hominis* \[[@pntd.0004729.ref051]\]. Our documentation of the predominance of *C*. *hominis* over *C*. *parvum* as a pathogen for human infants implies that vaccine development research should prioritize protection against this species and against anthroponotic (human host-restricted) subtypes of *C*. *parvum*. The lower incidence of *Cryptosporidium* disease in infants \<6 months old provides a window wherein multiple spaced doses of a future vaccine administered to infants may elicit protection for the subsequent increased risk of clinical *Cryptosporidium* disease encountered from age 6 to 23 months.

Our study has three obvious limitations. While we have extensive data on MSD cases from 7 sites over 4 years, we have only 1-year enrollment of LSD cases from 6 sites. Thus, estimates on children with LSD are less robust than for MSD. Second, we generated pooled estimates of disease incidence and mortality for SSA and I/P/B/N/A and assumed each to be representative of those regions. However, until locally-representative, standardized data become available, our approach is warranted. That *Cryptosporidium* appeared important as a pathogen in both urban and rural, high and low HIV settings, provides evidence that broad extrapolation is justified. Third, the species of a small fraction of *Cryptosporidium*-positive specimens remained unresolved because, although they were positive by EIA and PCR, we could not amplify the long fragments of DNA necessary for species-specific sequence determination of samples mostly with lower parasite load (average 18S PCR Ct 30±4 versus 21±5 for speciated samples, Mann-Whitney U test P\<0.001). That said, non-*hominis*/non-*parvum* species appeared to be quite rare. As for the species, the anthroponotic IIc and IIe were predominant *C*. *parvum* subtype families in this study with a larger portion of IIe than often appreciated \[[@pntd.0004729.ref039]\]. Similar findings on *C*. *parvum* subtypes have been described in India \[[@pntd.0004729.ref036]\]. Of 32 *C*. *hominis* infections with GP60 typing data, the predominant subtype families were Ia, Ib, and Ie. Ia had more diverse subtypes \[[@pntd.0004729.ref040],[@pntd.0004729.ref052]\], while Ie subtype was exclusively A11G3T3, consistent with previous reports \[[@pntd.0004729.ref036],[@pntd.0004729.ref039]\]. IbA13G3 infections appear to be common in West Africa. We found these in Mali (n = 4, 2 in cases) and Gambia (n = 4, all in cases), consistent with the high proportions previously seen in Ghana \[[@pntd.0004729.ref040]\]. The observation that the *C*. *parvum* parasites associated with MSD of young children in developing countries represent a restricted anthroponotic subset of all *C*. *parvum* is important as it enhances our ability to better understand the epidemiology of cryptosporidiosis and helps direct our vaccine development efforts.

Currently, there is little research to develop *Cryptosporidium* vaccines for humans and only one licensed drug, nitazoxanide, to ameliorate *Cryptosporidium* diarrhea in children \[[@pntd.0004729.ref053]\]. However, nitazoxanide is currently not recommended for use in infants \<12 months of age, exhibits little efficacy in HIV-infected hosts and evidence of efficacy from controlled pediatric trials is limited \[[@pntd.0004729.ref053]\]. The sizable case and death burden of *Cryptosporidium* in the SSA and I/P/B/N/A regions where \~80% of global deaths among young children occur calls for governments, global policymakers, and funding agencies to invest in developing new tools (e.g., vaccines) to prevent *Cryptosporidium* diarrheal illness and improved methods to diagnose and treat it, while also advocating increased access to improved sanitation and safe water.
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